Cargando…

Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland

BACKGROUND: Chronic hepatitis C virus infection is a major cause of liver disease in Switzerland and carries a significant cost burden. Currently, only conservative strategies are in place to mitigate the burden of hepatitis C in Switzerland. This study expands on previously described modeling effor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Müllhaupt, Beat, Bruggmann, Philip, Bihl, Florian, Blach, Sarah, Lavanchy, Daniel, Razavi, Homie, Semela, David, Negro, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480969/ https://www.ncbi.nlm.nih.gov/pubmed/26107467 http://dx.doi.org/10.1371/journal.pone.0125214

Ejemplares similares

HCV disease burden and population segments in Switzerland
por: Bihl, Florian, et al.
Publicado: (2021)

Progress toward implementing the Swiss Hepatitis Strategy: Is HCV elimination possible by 2030?
por: Müllhaupt, Beat, et al.
Publicado: (2018)

The impact of immigration on hepatitis B burden in the United States: a modelling study
por: Razavi-Shearer, Devin, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C
por: Pfeil, Alena M., et al.
Publicado: (2015)

Liver Disease Burden of Hepatitis C Virus Infection in Iran and the Potential Impact of Various Treatment Strategies on the Disease Burden
por: Hajarizadeh, Behzad, et al.
Publicado: (2016)

Impact of geographic origin on access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study
por: Brezzi, Matteo, et al.
Publicado: (2019)

Optimization of hepatitis C virus screening strategies by birth cohort in Italy
por: Kondili, Loreta A., et al.
Publicado: (2020)

All-Cause Mortality and Causes of Death in the Swiss Hepatitis C Cohort Study (SCCS)
por: Roelens, Maroussia, et al.
Publicado: (2020)

Chronic Hepatitis C Virus (HCV) Disease Burden and Cost in the United States
por: Razavi, Homie, et al.
Publicado: (2013)

Disease burden of hepatitis C in the Austrian state of Tyrol – Epidemiological data and model analysis to achieve elimination by 2030
por: Schaefer, Benedikt, et al.
Publicado: (2018)

Ten years countdown to hepatitis C elimination in Belgium: a mathematical modeling approach
por: Busschots, Dana, et al.
Publicado: (2022)

Hepatitis C elimination in Sweden: Progress, challenges and opportunities for growth in the time of COVID‐19
por: Blach, Sarah, et al.
Publicado: (2021)

Prevalence of hepatitis C in a Swiss sample of men who have sex with men: whom to screen for HCV infection?
por: Schmidt, Axel J, et al.
Publicado: (2014)

HCV elimination among people who inject drugs. Modelling pre- and post–WHO elimination era
por: Gountas, Ilias, et al.
Publicado: (2018)

Clinical Significance of the CCR5delta32 Allele in Hepatitis C
por: Morard, Isabelle, et al.
Publicado: (2014)

Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals
por: Gountas, Ilias, et al.
Publicado: (2019)

Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study
por: Lee, Kuan Ken, et al.
Publicado: (2019)

Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination
por: Brunner, Nathalie, et al.
Publicado: (2021)

Hepatitis C Virus Infection Trends in Italy
por: Lavanchy, Daniel
Publicado: (2012)

Characteristics of Foreign-Born Persons in the Swiss Hepatitis C Cohort Study: Implications for Screening Recommendations
por: Bertisch, Barbara, et al.
Publicado: (2016)

Modelling the microelimination of chronic hepatitis C in the canton of Bern, Switzerland: Reaching the Swiss Hepatitis Strategy goals despite the impact of the COVID 19 pandemic
por: Schorr, Olivier, et al.
Publicado: (2022)

A prospective, multicenter, post-marketing observational study to measure the quality of life of HCV genotype 1 infected, treatment naïve patients suffering from fatigue and receiving 3D regimen: The HEMATITE study
por: Semmo, Nasser, et al.
Publicado: (2020)

Disease burden of chronic hepatitis C in Brazil
por: Ferreira, Paulo Roberto Abrão, et al.
Publicado: (2015)

The Payer License Agreement, or “Netflix model,” for hepatitis C virus therapies enables universal treatment access, lowers costs and incentivizes innovation and competition
por: Matthews, David W., et al.
Publicado: (2022)

The Estimation of Economic Burden of Hepatitis C Virus Infection in Iran
por: MOHAMMADZADEH, Mehdi, et al.
Publicado: (2018)

Urgent action to fight hepatitis C in people who inject drugs in Europe
por: Dillon, John F., et al.
Publicado: (2016)

Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection
por: Kuntzen, Thomas, et al.
Publicado: (2016)

Modelling hepatitis B virus infection and impact of timely birth dose vaccine: A comparison of two simulation models
por: de Villiers, Margaret J., et al.
Publicado: (2020)

Economic burden of hepatitis C in Egypt: the future impact of highly effective therapies
por: Estes, C., et al.
Publicado: (2015)

Modeling HCV elimination recovery following the COVID-19 pandemic in the United States: Pathways to regain progress
por: Blach, Sarah, et al.
Publicado: (2023)

Epidemiology, Disease Burden, and Treatment Strategies of Chronic Hepatitis C Virus Infections in Saudi Arabia in the New Treatment Paradigm Shift
por: Aljumah, Abdulrahman A., et al.
Publicado: (2016)

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
por: Estes, Chris, et al.
Publicado: (2017)

Epidemiology of HEV Infection in Blood Donors in Southern Switzerland
por: Fontana, Stefano, et al.
Publicado: (2023)

Extrahepatic manifestations in hepatitis C virus infection
por: Negro, Francesco, et al.
Publicado: (2017)

Prevalence of Occult Hepatitis B Virus Infection in Blood Donors with Negative ID-NAT in Switzerland
por: Zbinden, Andrea, et al.
Publicado: (2022)

Progress Toward Hepatitis B and Hepatitis C Elimination Using a Catalytic Funding Model — Tashkent, Uzbekistan, December 6, 2019–March 15, 2020
por: Dunn, Rick, et al.
Publicado: (2020)

Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy
por: Reau, Nancy, et al.
Publicado: (2017)

Economic Burden of Hepatitis B Virus-Related Diseases: Evidence From Iran
por: Keshavarz, Khosro, et al.
Publicado: (2015)

Cost-effectiveness modelling of birth and infant dose vaccination against hepatitis B virus in Ontario from 2020 to 2050
por: Biondi, Mia J., et al.
Publicado: (2023)

Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach
por: Benzaken, Adele Schwartz, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_riucle0359gb1ojhhievgvdlg9